Dermira Inc. (NASDAQ:DERM) CFO Andrew Guggenhime sold 15,000 shares of the company’s stock in a transaction on Monday, September 19th. The stock was sold at an average price of $35.01, for a total value of $525,150.00. Following the sale, the chief financial officer now owns 20,116 shares of the company’s stock, valued at $704,261.16. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink.

Andrew Guggenhime also recently made the following trade(s):

  • On Monday, September 12th, Andrew Guggenhime sold 10,000 shares of Dermira stock. The shares were sold at an average price of $32.53, for a total value of $325,300.00.
  • On Thursday, August 11th, Andrew Guggenhime sold 10,000 shares of Dermira stock. The shares were sold at an average price of $31.02, for a total value of $310,200.00.
  • On Monday, July 11th, Andrew Guggenhime sold 10,000 shares of Dermira stock. The shares were sold at an average price of $30.15, for a total value of $301,500.00.

Dermira Inc. (NASDAQ:DERM) opened at 35.57 on Wednesday. The stock has a 50 day moving average price of $32.35 and a 200-day moving average price of $28.45. The company’s market capitalization is $1.26 billion. Dermira Inc. has a 52 week low of $17.42 and a 52 week high of $36.16.

This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at http://www.americanbankingnews.com/2016/09/21/insider-selling-dermira-inc-derm-cfo-sells-15000-shares-of-stock.html

Dermira (NASDAQ:DERM) last issued its earnings results on Monday, August 8th. The biopharmaceutical company reported ($0.89) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.86) by $0.03. On average, equities analysts predict that Dermira Inc. will post ($3.39) earnings per share for the current fiscal year.

A number of large investors have recently modified their holdings of the stock. TimesSquare Capital Management LLC boosted its stake in shares of Dermira by 79.3% in the second quarter. TimesSquare Capital Management LLC now owns 2,491,526 shares of the biopharmaceutical company’s stock worth $72,877,000 after buying an additional 1,101,645 shares during the last quarter. FMR LLC boosted its stake in shares of Dermira by 29.3% in the second quarter. FMR LLC now owns 4,063,136 shares of the biopharmaceutical company’s stock worth $118,847,000 after buying an additional 921,800 shares during the last quarter. Jennison Associates LLC boosted its stake in shares of Dermira by 52.0% in the second quarter. Jennison Associates LLC now owns 2,514,166 shares of the biopharmaceutical company’s stock worth $73,539,000 after buying an additional 860,597 shares during the last quarter. Loomis Sayles & Co. L P acquired a new stake in shares of Dermira during the second quarter worth about $10,678,000. Finally, Vanguard Group Inc. boosted its stake in shares of Dermira by 47.9% in the second quarter. Vanguard Group Inc. now owns 941,164 shares of the biopharmaceutical company’s stock worth $27,529,000 after buying an additional 304,750 shares during the last quarter. 82.46% of the stock is currently owned by institutional investors and hedge funds.

A number of research analysts have recently commented on the company. Zacks Investment Research upgraded Dermira from a “sell” rating to a “hold” rating in a research note on Tuesday, August 2nd. Needham & Company LLC increased their price target on Dermira from $42.00 to $46.00 and gave the company a “buy” rating in a research note on Thursday, June 2nd. Leerink Swann reiterated a “buy” rating and issued a $47.00 price target (up from $46.00) on shares of Dermira in a research note on Thursday, June 2nd. Finally, Wedbush increased their price target on Dermira from $42.00 to $46.00 and gave the company an “outperform” rating in a research note on Thursday, June 2nd. One equities research analyst has rated the stock with a hold rating and four have given a buy rating to the company. Dermira has a consensus rating of “Buy” and an average target price of $41.00.

About Dermira

Dermira, Inc is a biopharmaceutical company. The Company is focused on identifying, developing and commercializing differentiated therapies for dermatologic diseases. The Company’s portfolio includes three late-stage product candidates that target unmet needs and market opportunities, such as Cimzia (certolizumab pegol), DRM04 and DRM01.

5 Day Chart for NASDAQ:DERM

Receive News & Ratings for Dermira Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dermira Inc. and related companies with MarketBeat.com's FREE daily email newsletter.